Abstract
Purpose::
To evaluate intravitreal bevacizumab in patients with bilateral, idiopathic, acquired parafoveolar telangiectasis (2A)
Methods::
In a retrospective study the effect and safety of intravitreal bevacizumab (Avastin®) in 10 eyes of 8 patients with bilateral parafoveolar telangiectasis (group 2A) stages 3 to 5 were evaluated. Retreatment was based on fluorescein angiography (FA) and clinical appearance. Patients were monitored using visual acuity (VA), fluorescein angiography (FA), biomicroscopy and optical coherence tomography (OCT).
Results::
No safety concerns were apparent in up to 13 months (mean 5.5 months) follow-up. All eyes showed a reduction or resolution of leakage in FA at 1 month follow-up associated with an improvement in visual acuity. Mean visual acuity improved from 20/63 at baseline to 20/40 at month 3. Central retinal thickness (CRT) as measured by OCT was moderately reduced within the first 3 months from 247µm to 192µm. At the last follow-up visit (mean 5.5 months) VA remained stable at 20/40. The mean number of treatments required was 1.9.
Conclusions::
Intravitreal bevacizumab appears a promising treatment option for bilateral, idiopathic, acquired parafoveolar telangiectasis (2A) in short term follow-up.
Keywords: macula/fovea • edema • growth factors/growth factor receptors